Global Felodipine Sustained Release Tablet Market Size, Share and Trends Analysis Report, By Strength (2.5 mg, 5 mg, and Others), By Application (High Blood Pressure and Angina), Forecast Period (2022-2028)

The global felodipine sustained release tablet market is anticipated to grow at a significant CAGR of 6.2% during the forecast period (2022-2028). An increase in the geriatric population is going to drive the market further due to a decrease in the functionality of the body organs, more pressure is applied on the heart which results in high blood pressure, therefore in order to reduce blood pressure felodipine is used. In October 2021, according to WHO, the proportion of the globe’s population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050 which is anticipated to increase the demand for felodipine sustained release tablet which lowers blood pressure which lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

The increase in the use of tobacco and alcohol across the globe increases cardiovascular diseases like angina, as well as due to unhealthy diets and stressed routine increases the chances of cardiovascular diseases, hence it is also going to help in the growth of the felodipine sustained release tablet industry. For instance, in August 2021 according to WHO, hypertension affects an estimated 1.28 billion persons aged 30 to 79 globally, with the majority (two-thirds) residing in low- and middle-income nations. An estimated 46% of persons with hypertension are completely ignorant of their illness. More than half of persons with hypertension (42%) are diagnosed and treated.

Approximately one-fifth of persons with hypertension (21%) have it under control. Hypertension is a leading cause of death around the globe. Between 2010 and 2030, one of the global non-communicable disease targets is to lower the prevalence of hypertension by 33%. With such huge available as well as increasing consumer base is a major driving factor for the growth of felodipine sustained release tablet market in the forecasted period.

Some major players in the market include AstraZeneca PLC, Cipla Inc., Mylan N.V., Nanjing pharmaceutical factory Co, Ltd., Sandoz International GmbH, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Company Product Portfolio

Cipla Ltd offers Felogard 2.5 Tablet ER, It is used to treat hypertension (high blood pressure) and to avoid angina (heart-related chest pain). It belongs to the calcium channel blocker class of drugs, which helps to lower blood pressure and lessen the stress on the heart. This decreases the risk of heart attacks and strokes.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Strength
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- AstraZeneca PLC, Cipla Inc., Mylan N.V., Nanjing pharmaceutical factory Co, Ltd., Sandoz International GmbH, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Felodipine Sustained Release Tablet Market Report by Segment

By Strength

• 5mg
• 5mg
• Others (10mg)

 By Application

• High Blood Pressure
• Angina

Global Felodipine Sustained Release Tablet Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa